Public Employees Retirement System of Ohio Purchases New Shares in Zimmer Biomet Holdings, Inc. $ZBH

Public Employees Retirement System of Ohio purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 59,934 shares of the medical equipment provider’s stock, valued at approximately $5,160,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Zimmer Biomet in the second quarter worth $1,344,282,000. Primecap Management Co. CA acquired a new stake in Zimmer Biomet during the 2nd quarter worth about $328,578,000. Norges Bank purchased a new position in Zimmer Biomet during the 4th quarter valued at about $221,234,000. Bank of America Corp DE acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $187,480,000. Finally, Franklin Resources Inc. increased its holdings in shares of Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock valued at $601,204,000 after purchasing an additional 2,017,857 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

NYSE ZBH opened at $99.61 on Thursday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $106.88. The company has a fifty day simple moving average of $94.56 and a 200 day simple moving average of $91.58. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The company has a market cap of $19.00 billion, a P/E ratio of 24.24, a P/E/G ratio of 1.88 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter last year, the firm posted $2.07 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Zimmer Biomet’s payout ratio is currently 23.36%.

Analyst Ratings Changes

A number of brokerages have issued reports on ZBH. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Sanford C. Bernstein upped their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Wall Street Zen cut Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. BMO Capital Markets restated a “market perform” rating and issued a $96.00 target price on shares of Zimmer Biomet in a research note on Thursday, August 6th. Finally, Canaccord Genuity Group lifted their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.